Authors
Erica Ollmann Saphire, Sharon L Schendel, Marnie L Fusco, Karthik Gangavarapu, Bronwyn M Gunn, Anna Z Wec, Peter J Halfmann, Jennifer M Brannan, Andrew S Herbert, Xiangguo Qiu, Kshitij Wagh, Shihua He, Elena E Giorgi, James Theiler, Kathleen BJ Pommert, Tyler B Krause, Hannah L Turner, Charles D Murin, Jesper Pallesen, Edgar Davidson, Rafi Ahmed, M Javad Aman, Alexander Bukreyev, Dennis R Burton, James E Crowe, Carl W Davis, George Georgiou, Florian Krammer, Christos A Kyratsous, Jonathan R Lai, Cory Nykiforuk, Michael H Pauly, Pramila Rijal, Ayato Takada, Alain R Townsend, Viktor Volchkov, Laura M Walker, Cheng-I Wang, Larry Zeitlin, Benjamin J Doranz, Andrew B Ward, Bette Korber, Gary P Kobinger, Kristian G Andersen, Yoshihiro Kawaoka, Galit Alter, Kartik Chandran, John M Dye
Publication date
2018/8/9
Journal
Cell
Volume
174
Issue
4
Pages
938-952. e13
Publisher
Elsevier
Description
Antibodies are promising post-exposure therapies against emerging viruses, but which antibody features and in vitro assays best forecast protection are unclear. Our international consortium systematically evaluated antibodies against Ebola virus (EBOV) using multidisciplinary assays. For each antibody, we evaluated epitopes recognized on the viral surface glycoprotein (GP) and secreted glycoprotein (sGP), readouts of multiple neutralization assays, fraction of virions left un-neutralized, glycan structures, phagocytic and natural killer cell functions elicited, and in vivo protection in a mouse challenge model. Neutralization and induction of multiple immune effector functions (IEFs) correlated most strongly with protection. Neutralization predominantly occurred via epitopes maintained on endosomally cleaved GP, whereas maximal IEF mapped to epitopes farthest from the viral membrane. Unexpectedly, sGP cross …
Scholar articles
EO Saphire, SL Schendel, ML Fusco, K Gangavarapu… - Cell, 2018